Please login to the form below

Not currently logged in
Email:
Password:

LAMA/LABA

This page shows the latest LAMA/LABA news and features for those working in and with pharma, biotech and healthcare.

The end of pharma

The end of pharma

Looking back from the future, companies that marketed, say, insulin or LAMA/LABA drugs will seems like strange historical artefacts from another age.

Latest news

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    The data reveals that the drug was better than two-drug combinations in preventing COPD exacerbations, reducing attacks by 52% compared to AZ’s LAMA/LABA combination Bevespi (glycopyrronium/formoterol fumarate). ... There’s still all to play for, and

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    The real battleground between the two companies is expected to be three-drug combinations for COPD, with an inhaled corticosteroid (ICS) added to the LAMA/LABA duo. ... 2019. Given that the AERISTO trial compared the LAMA/LABA backbones of GSK and AZ’s

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol,

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    GSK thinks it has a decent head start with the triple therapy in a market increasingly crowded with LAMA/LABA and LABA/ICS combinations, and has suggested it could dominate the ... the new product with both ICS/LABA and LAMA/LABA combinations.

More from news
Approximately 2 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics